★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

Checking

Stock Profile

Elevance Health, Inc. (ELV) Moat Analysis

Elevance Health, Inc.

ELV · New York Stock Exchange

Market cap (USD)$86.9B
SectorHealthcare
IndustryMedical - Healthcare Plans
CountryUS
Data as of
Moat score
89/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Elevance Health operates Health Benefits, CarelonRx and Carelon Services. Its clearest moat is the Blue Cross Blue Shield license footprint: territory-based rights to use the Blue marks create a legally protected distribution and brand position in multiple states, although exclusivity is not universal. CarelonRx and Carelon Services have modest workflow switching costs where claims, member-service, care-management and utilization processes are integrated, and affiliated plans provide a built-in route for pharmacy bundling. Current economics temper the thesis: second-quarter Health Benefits operating margin fell to 2.1% as medical costs rose, and Carelon Services profit declined despite revenue growth. Membership size, government-program exposure and broad service menus were not scored independently because they do not alone establish an advantage.

Primary segment

Health Benefits

Market structure

Oligopoly

Market share

HHI:

Coverage

3 segments · 8 tags

Updated 2026-08-23

Segments

Health Benefits

U.S. health insurance and managed care

Revenue

85.4%

Structure

Oligopoly

Pricing

moderate

Share

Peers

UNHCVSCIHUM+2

CarelonRx

U.S. pharmacy benefit management and pharmacy services

Revenue

12.5%

Structure

Oligopoly

Pricing

weak

Share

Peers

CVSCIUNH

Carelon Services

U.S. healthcare services for payers and providers (care management, behavioral health, utilization management, care delivery)

Revenue

2.1%

Structure

Competitive

Pricing

moderate

Share

Peers

UNHCVSCIHUM

Moat Claims

Health Benefits

U.S. health insurance and managed care

Q2 2026 unaffiliated operating revenue was $42.720 billion and operating gain was $896 million. Revenue share is normalized to the $50.027 billion sum of unaffiliated revenue for Health Benefits, CarelonRx and Carelon Services, before the $201 million elimination. Operating profit share is normalized to the $1.844 billion operating-gain sum for those three segments, excluding Corporate & Other.

Oligopoly

Concession License

Legal

Strength

Strength 5 of 5

Durability

Durability 3 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

BCBSA license agreements grant (largely) exclusive rights to use Blue Cross / Blue Shield names and marks in assigned territories.

Concession License moat: definition, examples, and stocks

Erosion risks

  • BCBSA rule changes weakening exclusivity
  • License termination from non-compliance or change-of-control constraints
  • Antitrust/settlement changes enabling more second-bid competition for national accounts

Leading indicators

  • BCBSA compliance status (e.g., 80% revenue under BCBS marks requirement)
  • Material changes to BCBSA license terms or enforcement
  • BCBS-related litigation/regulatory outcomes affecting territory rules

Counterarguments

  • Exclusivity is not universal (some areas are non-exclusive)
  • Large employers can still shop across carriers; brand does not guarantee lowest total cost

Brand Trust

Demand

Strength

Strength 3 of 5

Durability

Durability 3 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

Blue Cross / Blue Shield branding and reputation can improve win rates and retention in employer, individual, and government markets.

Brand Trust moat: definition, examples, and stocks

Erosion risks

  • Negative publicity around insurers or prior authorization practices
  • Service quality issues impacting member/employer perception
  • Competitors increasing marketing spend and brand investment

Leading indicators

  • Retention in key commercial books (ASO and fully insured)
  • Customer complaint and regulator action trends
  • Brand tracking/NPS where disclosed

Counterarguments

  • Many buyers are price/network-driven and broker-mediated
  • Brand may matter less in employer ASO where cost and admin fees dominate

CarelonRx

U.S. pharmacy benefit management and pharmacy services

Q2 2026 unaffiliated operating revenue was $6.267 billion, affiliated revenue was $4.983 billion and operating gain was $582 million. Revenue and operating-profit shares use the same normalization described for Health Benefits.

Oligopoly

Data Workflow Lockin

Demand

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 3 of 5

Evidence

Evidence 1 of 5

PBM integrations (claims adjudication, drug data, member services) create operational switching costs for payers and employers.

Data Workflow Lockin moat: definition, examples, and stocks

Erosion risks

  • Standardized APIs and data portability reduce integration frictions
  • Clients carve out specialty pharmacy or point solutions
  • New entrants offering tech-first PBM administration

Leading indicators

  • Client churn / renewal rates
  • Average implementation time for new clients
  • Client satisfaction and service-level performance

Counterarguments

  • PBM switching is common; large buyers may accept transition costs to reduce net cost
  • Some PBM functionality is commoditized and interoperable

Suite Bundling

Demand

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 3 of 5

Evidence

Evidence 1 of 5

Distribution advantage from selling PBM services to Elevance-affiliated health plans plus external clients; supports cross-sell with medical and other Carelon services.

Suite Bundling moat: definition, examples, and stocks

Erosion risks

  • Purchasers push for best-of-breed vendors and unbundle PBM
  • Regulatory constraints on tying/bundling
  • Competitors bundle PBM + medical + services at larger scale

Leading indicators

  • Share of PBM business that is external vs affiliated
  • Cross-sell attach rates to medical membership
  • Pricing pressure in PBM RFPs

Counterarguments

  • Some buyers avoid bundled arrangements for transparency and cost benchmarking
  • Affiliated volume can be viewed as captive and does not guarantee external competitiveness

Carelon Services

U.S. healthcare services for payers and providers (care management, behavioral health, utilization management, care delivery)

Q2 2026 unaffiliated operating revenue was $1.040 billion, affiliated revenue was $6.935 billion and operating gain was $366 million. Revenue and operating-profit shares use the same normalization described for Health Benefits.

Competitive

Data Workflow Lockin

Demand

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 3 of 5

Evidence

Evidence 1 of 5

Care management, provider enablement, and utilization management workflows rely on data/analytics embedded in payer operations, raising switching costs.

Data Workflow Lockin moat: definition, examples, and stocks

Erosion risks

  • Data sharing restrictions and privacy regulation
  • Competitors with larger datasets and provider footprints
  • Analytics tooling commoditization (AI/automation)

Leading indicators

  • Contract renewal and retention rates for Carelon Services
  • Operational KPIs: turnaround times, authorization accuracy, provider satisfaction
  • Regulatory changes affecting data use (HIPAA/mental health parity, etc.)

Counterarguments

  • Payers frequently run UM/care management in-house or switch vendors via RFP
  • Switching costs may be moderate if processes are standardized

Evidence

sec_filing

exclusive, and in certain areas, non-exclusive, use of the Blue Cross and Blue Shield names and marks in assigned geographic territories

Supports the legal right-to-operate/brand licensing moat (territorial rights, compliance requirements, termination risk).

sec_filing

exclusive right to market products under the most recognized brand in the industry, BCBS

Management explicitly frames the Blue brand as a strategic asset supporting competitive positioning.

sec_filing

claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services

These are embedded workflows/data systems that typically require material integration work to replace.

sec_filing

affiliated health plan customers, as well as to external customers outside of the health plans we own

Indicates a built-in distribution channel (affiliated) plus external growth, enabling bundling/cross-sell.

sec_filing

leveraging data and insights to improve how our members receive safe, appropriate, high-quality care

Supports the workflow/data integration mechanism behind switching costs.

Risks & Indicators

Erosion risks

  • BCBSA rule changes weakening exclusivity
  • License termination from non-compliance or change-of-control constraints
  • Antitrust/settlement changes enabling more second-bid competition for national accounts
  • Negative publicity around insurers or prior authorization practices
  • Service quality issues impacting member/employer perception
  • Competitors increasing marketing spend and brand investment

Leading indicators

  • BCBSA compliance status (e.g., 80% revenue under BCBS marks requirement)
  • Material changes to BCBSA license terms or enforcement
  • BCBS-related litigation/regulatory outcomes affecting territory rules
  • Retention in key commercial books (ASO and fully insured)
  • Customer complaint and regulator action trends
  • Brand tracking/NPS where disclosed

Keep the research going

Created 2026-01-09
Updated 2026-08-23

More Rankings & Systems

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.